About Index Trending news
Analyze
Top 50 Pricing
bluebird bio

bluebird bio

Work at bluebird bio? Add yourself to this profile

bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. Our vision is to make the hope of gene therapy a reality.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital
$9,300,000
California Institute for Regenerative Medicine
Venture capital (Series D)
$60,000,000
Employees

Team size

50+
Locations
HQ
The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval

The Motley Fool

Here's Why bluebird bio.'s Stock Tumbled in March

The Motley Fool

Why bluebird bio's Stock Jumped 12.9% on Wednesday

The Motley Fool

Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals

The Motley Fool

Why Bluebird Bio Inc. Plunged Today

The Motley Fool

Why bluebird bio Inc Presented a Lower Price Today

The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Why bluebird bio Inc.'s Stock Dropped 34% in January

Stock markets
The Motley Fool

bluebird bio Inc. Takes Flight

Stock markets Health
The Motley Fool

Why Bluebird Bio Inc.'s Stock Bounced Back --

Stock markets Health
The Motley Fool

Why bluebird bio Inc's Stock Is Tanking Today --

Stock markets Health
The Motley Fool

Here's Why Bluebird Bio Turned in a Disappointing 2015 --

The Motley Fool

bluebird bio Inc: Gene Therapy Is (Still) Hard --

Health Stock markets
The Motley Fool

Clinical Data Whipsaws bluebird bio Inc. in November --